This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
by Zacks Equity Research
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.
PFENegative Net Change BMRNNegative Net Change NVONegative Net Change QURENegative Net Change
biotechs medical pharmaceuticals
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
by Zacks Equity Research
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
PFENegative Net Change AMGNNegative Net Change ALLOPositive Net Change SLNPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
by Zacks Equity Research
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
GSKNegative Net Change GILDNegative Net Change MIRMPositive Net Change CSTLPositive Net Change
biotechs
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
by Sundeep Ganoria
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.
VRTXNegative Net Change BEAMNegative Net Change EDITNegative Net Change CRSPNegative Net Change
biotechs crispr medical pharmaceuticals
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
by Zacks Equity Research
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
FATEPositive Net Change SPRONegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
by Zacks Equity Research
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
PFENegative Net Change GILDNegative Net Change ACRSPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
AZNPositive Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
by Zacks Equity Research
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
PFENegative Net Change GILDNegative Net Change EYENPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
by Zacks Equity Research
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
ALNYPositive Net Change PFENegative Net Change GILDNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
AZNPositive Net Change JNJPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Bull Of The Day: Tactile Systems Technology (TCMD)
by Brian Bolan
This stock consistently beats the number and treats underdiagnosed chronic diseases that could get more attention with the changes coming to the government
TCMDNegative Net Change
biotechnology biotechs medical medical-devices
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
by Zacks Equity Research
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
MRKNegative Net Change SMMTPositive Net Change TILPositive Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
Trump Taps RFK for HHS: Time to Avoid Biotech?
by Andrew Rocco
With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers. Stock Strategist Andrew Rocco explains.
PFENegative Net Change NVONegative Net Change MCDNegative Net Change MRNANegative Net Change XBINegative Net Change
biotechnology biotechs
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
NVSPositive Net Change PFENegative Net Change KODPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
BIIBNegative Net Change LLYNegative Net Change PRTANegative Net Change
biotechs
Vaccine Stocks Fall After Trump Selects RFK Jr. to Lead HHS
by Sundeep Ganoria
President-elect Donald Trump picks Robert F. Kennedy Jr., a prominent vaccine skeptic, as the next health secretary of the HHS.
PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
by Zacks Equity Research
AMGN says there was no connection between the administration of MariTide and bone mineral density changes.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechs
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
by Zacks Equity Research
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
NVAXPositive Net Change RNANegative Net Change SNDXNegative Net Change
biotechnology biotechs medical pharmaceuticals
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
SMMTPositive Net Change TILPositive Net Change CSTLPositive Net Change BNTXPositive Net Change
biotechs
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
by Zacks Equity Research
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
BIIBNegative Net Change ABBVNegative Net Change SYRSNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
RNA Stock Hits Record High on Entering the Cardiac Disease Space
by Zacks Equity Research
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
BIIBNegative Net Change RNANegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
BIIBNegative Net Change TBPHNegative Net Change ALLOPositive Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
ANIPNo Net Change FATEPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
by Zacks Equity Research
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
JAZZPositive Net Change ANIPNo Net Change AXSMPositive Net Change CSTLPositive Net Change
biotechs earnings
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
BIIBNegative Net Change NBIXNegative Net Change XENEPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals